BIOTRONIK Blog

BIOTRONIK has enrolled the first patients in its BIO-OSCAR FIRST trial, a study designed to confirm the safety and clinical performance of the Oscar ® Peripheral Multifunctional Catheter for dilation of lesions in the femoral, popliteal and infrapopliteal arteries 1, including both above-the-knee (ATK) and below-the-knee (BTK) lesions. The BIO-OSCAR FIRST trial is a prospective, multicenter, single-arm observational study involving 16 European sites within CE-mark accepting territories. Over the next 12 months, the trial aims to enroll 200 subjects - 100 for ATK and 100 for BTK lesions. This

BIOTRONIK has concluded the BIO-OSCAR SOC, a prospective, multicenter, observational trial. It is intended at evaluating current standard of care practices, procedural outcomes, complication handling and device use in endovascular treatments for atherosclerotic lesions both above the knee (ATK) and below the knee (BTK). The outcomes were presented today at the Paris Vascular Insights Course 2024 by Dr. Koen Deloose, principal investigator of the BIO-OSCAR SOC. The study analyzed data from 247 patients across 16 European CE-mark territories, aiming to deliver insights into real-world practices

The Digital Heart Summit 2024, held in Berlin on October 25-26th, concluded with resounding success, bringing together leading minds in eHealth to explore the cutting-edge innovations in digital cardiology. The summit attracted over 100 cardiologists, researchers, and tech innovators from across Europe, making it an excellent platform for interactive exchange and diverse insights in this fast-evolving field. Throughout the two-day event, attendees engaged in discussions on the latest advancements in artificial intelligence, telemedicine, and wearable health devices. These technologies are